Guggenheim Initiates Buy Rating for CG Oncology (CGON)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 18 2025
0mins
Should l Buy CGON?
Source: Yahoo Finance
Investment Rating: CG Oncology, Inc. (NASDAQ: CGON) received a Buy rating from Guggenheim analyst Brad Canino, with a price target of $90, highlighting its potential in the oncology market.
Product Development: The company's product, cretostimogene, is set for FDA review in 2026 and is noted for its "best-in-class" efficacy and safety, aimed at treating Non-Muscle Invasive Bladder Cancer (NMIBC).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGON
Wall Street analysts forecast CGON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 51.620
Low
65.00
Averages
79.73
High
108.00
Current: 51.620
Low
65.00
Averages
79.73
High
108.00
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer during the GOBLET Cohort 4, significantly exceeding the historical benchmark of 10%, indicating its crucial clinical value in a setting with no FDA-approved treatment options.
- Duration of Response: Among 14 evaluable patients, the median duration of response for pelareorep reached approximately 17 months, far surpassing the standard treatment's 9.5 months, showcasing the drug's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for potential accelerated approval if the data is validated.
- Strategic Investment and Expert Support: The company expanded its Scientific Advisory Board by adding three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, further strengthening its strategic positioning in the gastrointestinal oncology field.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer patients during the GOBLET Cohort 4 study, significantly surpassing the historical benchmark of 10%, indicating the therapy's substantial potential in a patient population with no FDA-approved options.
- Duration of Response: The study also revealed a median duration of response of approximately 17 months, far exceeding the standard treatment's 9.5 months, suggesting that pelareorep offers durable efficacy in heavily pretreated patients, addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for accelerated approval if the observed data can be replicated.
- Strategic Investment and Expansion: The company is enhancing its strategic positioning in gastrointestinal oncology by expanding its Scientific Advisory Board, further solidifying its market presence in anal cancer and other indications.
See More
Rich Sparkle Holdings Signs $39 Million Share Offering Agreement
- Stock Surge: Rich Sparkle Holdings Ltd's shares skyrocketed 115% to $52.00 following the signing of a $39 million agreement for 3 million ordinary shares, indicating strong market confidence in its financing strategy.
- Positive Market Reaction: The offering price of $13 per share is significantly lower than the current market price, reflecting optimistic investor expectations regarding the company's growth potential, which may provide essential funding for future expansions.
- Significant Industry Impact: The successful financing of Rich Sparkle Holdings not only enhances its market position but could also attract more investor attention to the sector, potentially driving up stock prices of related companies.
- Optimistic Future Outlook: With the influx of capital, the company is poised to accelerate its business development and market expansion, further solidifying its competitive advantage in the industry.
See More
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
- Significant Stock Surge: Shares of CG Oncology Inc soared 21.8% to $51.05 after the announcement of an expedited topline data readout for the PIVOT-006 clinical trial, reflecting strong market confidence in the company's future prospects.
- Clinical Trial Advancement: The trial compares adjuvant intravesical treatment versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer, and the earlier data release is expected to attract more investor interest, further propelling the company's growth.
- Positive Market Reaction: This stock price increase not only indicates investor optimism about CG Oncology's potential but may also enhance the company's financing capabilities in the biopharmaceutical sector, strengthening its competitive position.
- Significant Industry Impact: CG Oncology's progress could influence treatment standards for non-muscle invasive bladder cancer, prompting other companies in the industry to accelerate their R&D efforts, thereby boosting overall market vitality.
See More
CG Oncology Accelerates PIVOT-006 Data Timeline to 1H 2026
- Accelerated Data Release: CG Oncology announced that topline data from the PIVOT-006 clinical trial is now expected in the first half of 2026, nearly a year ahead of schedule, demonstrating the company's rapid progress in the intermediate-risk non-muscle invasive bladder cancer (NMIBC) space.
- Broad Participation: The trial has enrolled over 360 patients across more than 90 sites, highlighting the urgent need for new therapies in this area and laying the groundwork for the company's future market expansion.
- Market Potential: The intermediate-risk NMIBC patient population in the U.S. is estimated to exceed 50,000, and CG Oncology aims to broaden its market reach with this innovative therapy to address unmet medical needs.
- Innovative Treatment: Cretostimogene is a novel oncolytic immunotherapy, with ongoing clinical development including two Phase 3 trials, showcasing the company's strategic positioning and potential market leadership in bladder cancer treatment.
See More
Inaugural Week of CGON Options Trading for February 2026
Put Contract Overview: The $35.00 put contract for CGON has a bid of 30 cents, allowing investors to buy shares at a cost basis of $34.70, which is a 10% discount from the current price of $38.77. There is a 68% chance the contract may expire worthless, offering a potential 0.86% return on cash commitment.
Call Contract Overview: The $40.00 call contract has a bid of $1.50, and if shares are purchased at $38.77 and the call is sold, it could yield a total return of 7.04% if exercised by February 2026. There is a 50% chance this contract may also expire worthless, providing a potential 3.87% additional return.
Volatility Insights: The implied volatility for the put contract is 68% and for the call contract is 69%, while the actual trailing twelve-month volatility is calculated at 66%, indicating a relatively stable trading environment for CGON.
YieldBoost Concept: The article discusses the concept of YieldBoost, highlighting potential returns from both the put and call contracts, which can enhance overall investment returns for investors considering options trading strategies.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer during the GOBLET Cohort 4, significantly exceeding the historical benchmark of 10%, indicating its crucial clinical value in a setting with no FDA-approved treatment options.
- Duration of Response: Among 14 evaluable patients, the median duration of response for pelareorep reached approximately 17 months, far surpassing the standard treatment's 9.5 months, showcasing the drug's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for potential accelerated approval if the data is validated.
- Strategic Investment and Expert Support: The company expanded its Scientific Advisory Board by adding three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, further strengthening its strategic positioning in the gastrointestinal oncology field.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer patients during the GOBLET Cohort 4 study, significantly surpassing the historical benchmark of 10%, indicating the therapy's substantial potential in a patient population with no FDA-approved options.
- Duration of Response: The study also revealed a median duration of response of approximately 17 months, far exceeding the standard treatment's 9.5 months, suggesting that pelareorep offers durable efficacy in heavily pretreated patients, addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for accelerated approval if the observed data can be replicated.
- Strategic Investment and Expansion: The company is enhancing its strategic positioning in gastrointestinal oncology by expanding its Scientific Advisory Board, further solidifying its market presence in anal cancer and other indications.
See More
Rich Sparkle Holdings Signs $39 Million Share Offering Agreement
- Stock Surge: Rich Sparkle Holdings Ltd's shares skyrocketed 115% to $52.00 following the signing of a $39 million agreement for 3 million ordinary shares, indicating strong market confidence in its financing strategy.
- Positive Market Reaction: The offering price of $13 per share is significantly lower than the current market price, reflecting optimistic investor expectations regarding the company's growth potential, which may provide essential funding for future expansions.
- Significant Industry Impact: The successful financing of Rich Sparkle Holdings not only enhances its market position but could also attract more investor attention to the sector, potentially driving up stock prices of related companies.
- Optimistic Future Outlook: With the influx of capital, the company is poised to accelerate its business development and market expansion, further solidifying its competitive advantage in the industry.
See More
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
- Significant Stock Surge: Shares of CG Oncology Inc soared 21.8% to $51.05 after the announcement of an expedited topline data readout for the PIVOT-006 clinical trial, reflecting strong market confidence in the company's future prospects.
- Clinical Trial Advancement: The trial compares adjuvant intravesical treatment versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer, and the earlier data release is expected to attract more investor interest, further propelling the company's growth.
- Positive Market Reaction: This stock price increase not only indicates investor optimism about CG Oncology's potential but may also enhance the company's financing capabilities in the biopharmaceutical sector, strengthening its competitive position.
- Significant Industry Impact: CG Oncology's progress could influence treatment standards for non-muscle invasive bladder cancer, prompting other companies in the industry to accelerate their R&D efforts, thereby boosting overall market vitality.
See More
CG Oncology Accelerates PIVOT-006 Data Timeline to 1H 2026
- Accelerated Data Release: CG Oncology announced that topline data from the PIVOT-006 clinical trial is now expected in the first half of 2026, nearly a year ahead of schedule, demonstrating the company's rapid progress in the intermediate-risk non-muscle invasive bladder cancer (NMIBC) space.
- Broad Participation: The trial has enrolled over 360 patients across more than 90 sites, highlighting the urgent need for new therapies in this area and laying the groundwork for the company's future market expansion.
- Market Potential: The intermediate-risk NMIBC patient population in the U.S. is estimated to exceed 50,000, and CG Oncology aims to broaden its market reach with this innovative therapy to address unmet medical needs.
- Innovative Treatment: Cretostimogene is a novel oncolytic immunotherapy, with ongoing clinical development including two Phase 3 trials, showcasing the company's strategic positioning and potential market leadership in bladder cancer treatment.
See More
Inaugural Week of CGON Options Trading for February 2026
Put Contract Overview: The $35.00 put contract for CGON has a bid of 30 cents, allowing investors to buy shares at a cost basis of $34.70, which is a 10% discount from the current price of $38.77. There is a 68% chance the contract may expire worthless, offering a potential 0.86% return on cash commitment.
Call Contract Overview: The $40.00 call contract has a bid of $1.50, and if shares are purchased at $38.77 and the call is sold, it could yield a total return of 7.04% if exercised by February 2026. There is a 50% chance this contract may also expire worthless, providing a potential 3.87% additional return.
Volatility Insights: The implied volatility for the put contract is 68% and for the call contract is 69%, while the actual trailing twelve-month volatility is calculated at 66%, indicating a relatively stable trading environment for CGON.
YieldBoost Concept: The article discusses the concept of YieldBoost, highlighting potential returns from both the put and call contracts, which can enhance overall investment returns for investors considering options trading strategies.
See More
